Comparative Pharmacology
Head-to-head clinical analysis: ELFABRIO versus PALYNZIQ.
Peer-Reviewed Evidence
Head-to-head clinical analysis: ELFABRIO versus PALYNZIQ.
ELFABRIO vs PALYNZIQ
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Recombinant human α-galactosidase A enzyme that hydrolyzes globotriaosylceramide (Gb3) and other glycosphingolipids with terminal α-galactosyl groups, thereby reducing accumulation in tissues.
PALYNZIQ (pegvaliase-pqpz) is a recombinant phenylalanine ammonia lyase conjugated to polyethylene glycol. It converts phenylalanine to trans-cinnamic acid and ammonia, reducing blood phenylalanine levels in patients with phenylketonuria.
1 mg/kg intravenously over 2 hours every 2 weeks.
2.4 mg subcutaneously once daily.
None Documented
None Documented
Terminal elimination half-life approximately 0.5–1 hour; short half-life necessitates twice-weekly intravenous dosing.
Approximately 60–80 hours (terminal half-life); supports weekly dosing regimen.
Primarily eliminated via renal excretion as intact protein; minimal biliary/fecal elimination (<1%).
Renal (predominantly as intact pegylated enzyme); less than 5% fecal. No active metabolites.
Category C
Category C
Enzyme Replacement Therapy
Enzyme Replacement Therapy